MONTREAL, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Nano Graphene Inc. dba GrapheneCA (“GrapheneCA”) proudly announced today that its graphene can readily be put to use in a number of pharmaceutical fields and the cosmetic industry. This paves the way for the introduction and licensing of highly innovative alternatives to conventional products on the market today.
In successfully implementing the company’s second New York-based production line, GrapheneCA has proved scalability, and is already making known its plans to inaugurate a production facility for cosmetics and pharmaceutical grade graphene in Canada by the end of 2019.
“Not only has GrapheneCA succeeded in producing pure graphene that is suitable for medical and pharmaceutical applications, but it has standardized its manufacturing process and is deploying efforts to provide whole package solutions, using its own graphene technology, which industries need and are looking for,” explained Alex Hamouti, Montreal-based Head of Cosmetic and Dental Hygiene Development for GrapheneCA.
“To be suitable for cosmetics and pharmaceutical use, graphene must have a very high level of purity and be non-toxic; this constraint is of paramount importance, one to which we respond with a highly efficient proprietary production process,” he went on to say.
“Graphene has unique properties that make it an extremely promising material for innumerable biotech applications; what interests these industries in particular is graphene’s antibacterial characteristics, its conductive and thermal properties, as well as its uncanny ability to facilitate absorption of active ingredients. Recent research also demonstrates that graphene has highly biocompatible.”
ABOUT GRAPHENECA
GrapheneCA is a privately owned, commercial scale graphene and graphene-based materials producer, and supply company headquartered in New York. It is dedicated to tackling the challenge of integrating graphene into real-world applications through the use of its own highly effective, scalable, and environmentally friendly production process. GrapheneCA has developed a production facility in New York and currently produces stacked graphite flakes with less than 0.03% oxygen contamination on a large scale. GrapheneCA has applied for patents in the USA and China.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to GrapheneCA, including: information relating to the business plans of GrapheneCA; GrapheneCA opening a production facility for cosmetics and pharmaceutical grade graphene in Canada by the end of 2019; and the future uses of graphene, are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect GrapheneCA’s current views and intentions with respect to future events, and current information available to GrapheneCA, and are subject to certain risks, uncertainties and assumptions. Material factors or assumptions were applied in providing forward-looking information, including GrapheneCA successfully mass-producing graphene and graphene becoming adopted by the markets. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: changes in law; the ability to implement business strategies and pursue business opportunities; state of the capital markets; the availability of funds and resources to pursue operations; a novel business model; dependence on key suppliers and local partners; competition; the outcome and cost of any litigation; as well as general economic, market and business conditions. Should any factor affect GrapheneCA in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, GrapheneCA does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and GrapheneCA undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. GrapheneCA’s results and forward-looking information and calculations may be affected by fluctuations in exchange rates.
For further information, please contact:
| Canada Martin Tremblay Investment Counselor +1-514 566-6606 mtremblay@hamsacapital.com | International Peter Nesveda International Corporate Affairs +61 (0) 412 357 375 pnesveda@graphene.ca | USA David Robles Head of Business Development +1-646-696-0679 drobles@graphene.ca |
